Ivonescimab Plus Chemotherapy Fails Cost-Effectiveness Test in Advanced Squamous Lung Cancer
A cost-effectiveness model based on the HARMONi-6 trial finds that ivonescimab plus chemotherapy is unlikely to be cost-effective for advanced ...
A cost-effectiveness model based on the HARMONi-6 trial finds that ivonescimab plus chemotherapy is unlikely to be cost-effective for advanced ...
A new position paper in Pharmacia finds the economic case for therapeutic drug monitoring of biologics rests on just two ...
A 20-year Markov modeling study from Bulgaria finds that adding treatment-free remission phases to chronic myeloid leukemia care lowers costs ...
A Bulgarian real-world economic model finds that venetoclax plus azacitidine improves survival and quality of life in older AML patients ...
A new Italian Medicines Agency analysis shows that medicines without market competition consumed 9.6 billion euros, or 38.6 percent, of ...
A new study in the Journal of General Internal Medicine examines how manufacturer coupons reshape patient and payer spending across ...
An interrupted time-series analysis of nearly 10,000 medicine presentations shows that Argentina's December 2023 economic shock left minimum-pension retirees facing ...
A Taiwanese cost-utility analysis finds atogepant's cost-effectiveness for episodic migraine prevention hinges on quality-of-life assumptions and willingness-to-pay thresholds.
A new letter to the editor in the Journal of General Internal Medicine critically examines real-world evidence on insulin glargine ...
A real-world time-series analysis published in the Journal of General Internal Medicine finds that the first biosimilar insulin glargine did ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine